

Interview Summary	Application No.	Applicant(s)	
	10/791,862	POPP, KARL F.	
	Examiner	Art Unit	
	Lakshmi S. Channavajjala	1615	

All participants (applicant, applicant's representative, PTO personnel):

- (1) Lakshmi S. Channavajjala. (3) Fred Wolf.
 (2) Joshua Goldberg. (4) _____

Date of Interview: 16 October 2007.

Type: a) ☐ Telephonic b) ☐ Video Conference
 c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.
 If Yes, brief description: _____

Claim(s) discussed: on record.

Identification of prior art discussed: on record.


Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.



 Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Attorney explained that the double patenting rejections will be obviated by way of amending the claims in the co-pending applications. Discussed the differences between acne and rosacea, that benzoyl peroxide actually causes rosacea rather than provide treatment and the examiner was informed that evidence showing the same will be filed. Examiner suggested amending the claims to recite the amount of benzoyl peroxide or an effective amount of clindamycin and an effective amount of benzoyl peroxide for treating rosacea. Examiner will consider the evidence and the amendment submitted with the response in determining the patentability. Applicants will amend claim 29 to recite "eliminating mite organism from the skin" and in response to the 35 USC 112, 2nd paragraph rejection, will cancel claim 26.